The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine

Peter Lin, Lehua Chang, Robert J. DeVita, Jonathan R. Young, Ronsar Eid, Xinchun Tong, Song Zheng, Richard G. Ball, Nancy N. Tsou, Gary G. Chicchi, Marc M. Kurtz, Kwei Lan C. Tsao, Alan Wheeldon, Emma J. Carlson, Wai Si Eng, H. Donald Burns, Richard J. Hargreaves, Sander G. Mills

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

SAR studies on amides, ureas, and vinylogous amides derived from pyrrolidine led to the discovery of several potent hNK1 antagonists. One particular vinylogous amide (45b) had excellent potency, selectivity, pharmacokinetic profile, and functional activity in vivo. An in vivo rhesus macaque brain receptor occupancy PET study for compound 45b revealed an estimated Occ90 ∼ 300 ng/ml.

Original languageEnglish
Pages (from-to)5191-5198
Number of pages8
JournalBioorganic and Medicinal Chemistry Letters
Volume17
Issue number18
DOIs
StatePublished - 15 Sep 2007
Externally publishedYes

Keywords

  • NK
  • Neurokinin NK antagonist
  • Substance P antagonist
  • Tachykinin NK antagonist

Fingerprint

Dive into the research topics of 'The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine'. Together they form a unique fingerprint.

Cite this